Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-25-007012
Filing Date
2025-01-27
Accepted
2025-01-27 16:30:08
Documents
16
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K ea0228749-10ka1_citius.htm   iXBRL 10-K/A 239052
2 CERTIFICATION ea022874901ex31-3_citius.htm EX-31.3 3572
3 CERTIFICATION ea022874901ex31-4_citius.htm EX-31.4 3876
  Complete submission text file 0001213900-25-007012.txt   478320

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tenk-20240930.xsd EX-101.SCH 3052
5 XBRL LABEL FILE tenk-20240930_lab.xml EX-101.LAB 33480
6 XBRL PRESENTATION FILE tenk-20240930_pre.xml EX-101.PRE 17293
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0228749-10ka1_citius_htm.xml XML 7398
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6677
CITIUS ONCOLOGY, INC. (Filer) CIK: 0001851484 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0930
Type: 10-K/A | Act: 34 | File No.: 001-41534 | Film No.: 25559429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)